Search results
Results from the WOW.Com Content Network
Proposed CDBG projects must be consistent with broad national priorities for CDBG: activities that benefit low- and moderate-income people, the prevention or elimination of slums or blight, or other community development activities to address an urgent threat to health or safety. CDBG funds may be used for community development activities (such ...
The Drug-Free Workplace Act of 1988 (41 U.S.C. 81) is an Act of the United States which requires some federal contractors and all federal grantees to agree that they will provide drug-free workplaces as a precondition of receiving a contract or grant from a Federal agency. [1]
The Community Services Block Grant (CSBG) provides federal funding for Community Action Agencies (CAAs) and other programs that seek to address poverty at the community level.
All U.S. states are automatically eligible for HOME funds, and each receives a minimum of $3 million for the program, while local governments receive a minimum of $500,000 (unless the United States Congress assigns $1.5 billion or less to the program, in which case they receive a minimum of $335,000). [2]
The Alcohol, Drug Abuse, and Mental Health Services Block Grant (ADMS block grant) was created in August 1981 with passage the Omnibus Budget Reconciliation Act of 1981. [1]
The drug or other substance has a high potential for abuse. The drug or other substance has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use of the drug or other substance under medical supervision. The complete list of Schedule I substances is as follows. [1]
The Safe and Drug-Free Schools and Communities Advisory Committee, authorized by the No Child Left Behind Act, was appointed by the U.S. Secretary of Education Margaret Spellings. The Committee was established to provide advice to the Secretary on Federal, state, and local programs designated to create safe and drug-free schools, and on issues ...
The 340B Drug Pricing Program is a US federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. The intent of the program is to allow covered entities to "stretch scarce federal resources as far as possible ...